title: Montelukast abrogates rhabdomyolysis-induced acute renal failure via rectifying detrimental changes in antioxidant profile and systemic cytokines and apoptotic factors production.
abstract: In addition to antiasthmatic effect, the cysteinyl leukotriene receptor 1 (CysLT₁) antagonist montelukast shows renoprotective effect during ischemia/reperfusion and cyclosporine-induced renal damage. Here, we proposed that montelukast protects against rhabdomyolysis-induced acute renal failure. Compared with saline-treated rats, at 48 h following the induction of rhabdomyolysis using intramuscular glycerol (10 ml 50% glycerol/kg), significant elevations in serum levels of urea, creatinine, phosphate and acute renal tubular necrosis were observed. This was associated with elevations in serum Fas, interleukin-10, tumor necrotic factor-alpha, and transforming growth factor-beta1 and renal malondialdehyde and nitrite and detrimental reductions in renal catalase and superoxide dismutase activities. The effects of rhabdomyolysis on renal functional, biochemical and structural integrity and the associated changes in cytokines and Fas levels were abolished upon concurrent administration of montelukast (10 mg/kg i.p.) for 3 days (1 day before and 2 days after induction of rhabdomyolysis). Alternatively, administration of the anti-oxidant, α-tocopherol (400 mg/kg i.m.) for 3 days, succeeded in alleviating renal oxidative stress, but had no significant effect on the circulating levels of most cytokines and partially restored kidney functional and structural damage. Serum level of interleukin-6 was not altered by rhabdomyolysis but showed significant elevations in rats treated with montelukast or α-tocopherol. Collectively, motelukast abrogated functional and structural renal damage induced by rhabdomyolysis via ameliorating renal oxidative stress and modulation of systemic cytokines and apoptotic factors production. The results of this work are expected to open new avenues for early prevention of rhabdomyolysis-induced acute renal failure using selective CysLT₁ antagonists such as montelukast.
authors.affiliation: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
authors.forename: Mai M
authors.initials: MM
authors.lastname: Helmy
authors.forename: Hanan M
authors.initials: HM
authors.lastname: El-Gowelli
mesh_terms: D000085:Acetates / Q000627:therapeutic use*; D000818:Animals; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D003521:Cyclopropanes; D016207:Cytokines / Q000097:blood*; D053200:Fas-Associated Death Domain Protein / Q000097:blood*; D005990:Glycerol; D007668:Kidney / Q000187:drug effects / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D007683:Kidney Tubular Necrosis, Acute / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D010088:Oxidoreductases / Q000378:metabolism*; D011804:Quinolines / Q000627:therapeutic use*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D018077:Receptors, Leukotriene / Q000737:chemistry / Q000378:metabolism; D012206:Rhabdomyolysis / Q000139:chemically induced / Q000503:physiopathology*; D013440:Sulfides; D024502:alpha-Tocopherol / Q000627:therapeutic use
chemical_list: D000085:Acetates; D018927:Anti-Asthmatic Agents; D000975:Antioxidants; D003521:Cyclopropanes; D016207:Cytokines; C505535:Fadd protein, rat; D053200:Fas-Associated Death Domain Protein; D020024:Leukotriene Antagonists; D011804:Quinolines; D018077:Receptors, Leukotriene; D013440:Sulfides; D008315:Malondialdehyde; D010088:Oxidoreductases; D024502:alpha-Tocopherol; C083169:leukotriene D4 receptor; C093875:montelukast; D005990:Glycerol